Kivo will showcase its AI-enabled Headless GxP platform at RAPS Convergence 2026, as life sciences organisations continue to examine how artificial intelligence can be used in regulated environments.
The company will exhibit at Booth 706 during the event, which takes place from 15-17 September 2026 at the Charlotte Convention Center in Charlotte, North Carolina.
Kivo describes Headless GxP as an agent-native architecture designed to help regulatory, clinical and quality teams operationalise AI while maintaining compliance controls, human oversight and traceability.
AI in regulated life sciences workflows
Life sciences companies are under growing pressure to adopt AI across document-heavy and process-heavy functions, including regulatory operations, clinical trial management, quality systems and submission preparation.
However, the use of AI in regulated environments raises practical questions around audit trails, permissions, validation, data governance and who is accountable for compliance-significant actions.
Kivo’s Headless GxP approach is designed to allow external AI agents to work alongside people by accessing regulated content and metadata, surfacing insights and recommending next steps.
According to Kivo, actions that carry compliance significance remain inside the company’s validated application, where authenticated users review, approve and execute work with traceability.
“We’re very excited to bring Headless GxP to the RAPS Convergence event,” said Toban Zolman, CEO of Kivo.
“Since launching in June, the response from our early-access programme customers has been overwhelmingly positive, confirming our hypothesis that life sciences teams are looking for solutions that allow them to leverage the advantages of AI-driven workflows while maintaining GxP compliance.”
Live demonstrations at RAPS Convergence
Kivo said its live demonstrations will show how pharma, biotech and clinical research organisations can begin using AI within regulated operating environments.
The demos will focus on how AI agents can securely access regulated content, analyse documents and metadata, surface insights and support human decision-making.
Headless GxP is positioned for teams working across regulatory information management, electronic trial master files, quality management systems, controlled documents, submissions, inspection readiness, SOPs and training management.
“Kivo is proud to be part of the conversations shaping the future of regulatory operations,” said Jianna Lieberman, Vice President of Marketing and Revenue Operations at Kivo and a member of the RAPS Convergence Exhibitor Advisory Committee.
“We’re looking forward to connecting with attendees and demonstrating how open, AI-ready platforms can help organisations actually embrace agentic AI in the most responsible way.”
Regulatory technology and AI governance
RAPS Convergence is a major event for regulatory affairs professionals across pharmaceutical, biotechnology, medical device and digital health organisations.
The 2026 event will bring together regulatory leaders to discuss advances in regulatory science, technology and compliance, including how new digital tools are reshaping life sciences operations.
Attendees can visit Kivo at Booth 706 during the conference or request a demonstration through Kivo’s demo page.
FAQs
What is Kivo Headless GxP?
Kivo Headless GxP is an architecture designed to let AI agents interact with regulated life sciences content while keeping compliance controls, permissions and audit trails inside Kivo’s validated system of record.
Where will Kivo demonstrate Headless GxP?
Kivo will demonstrate Headless GxP at Booth 706 during RAPS Convergence 2026 in Charlotte, North Carolina.
When is RAPS Convergence 2026?
RAPS Convergence 2026 takes place from 15-17 September 2026 at the Charlotte Convention Center.
Which life sciences teams is Headless GxP designed for?
The platform is designed for regulatory, clinical and quality teams working in regulated life sciences environments.
How does Kivo approach AI compliance?
Kivo says AI agents can analyse and recommend actions, while compliance-significant actions remain inside its validated application for human review, approval and execution.
